What is GenrAb?
GenrAb is a biotechnology firm dedicated to pioneering neuroprotective therapies by leveraging the human immune system. The company employs its proprietary Antibody Gene Signature technology to identify fully-human monoclonal antibodies with therapeutic potential. Their lead candidate, TGM-010, is designed to prevent disease progression and improve patient care in various neurodegenerative disorders. GenrAb's mission extends beyond scientific advancement to making a substantial impact on patient lives through transformative neurological care.
How much funding has GenrAb raised?
GenrAb has raised a total of $5.6M across 1 funding round:
Angel/Seed
$5.6M
Angel/Seed (2025): $5.6M with participation from Actium Group
Key Investors in GenrAb
Actium Group
Actium Group is a consulting firm focused on identifying growth opportunities and providing comprehensive project planning and cost analysis. They partner selectively with clients, offering personalized guidance and support based on over a decade of industry experience.
What's next for GenrAb?
The substantial enterprise-level backing positions GenrAb for significant scaling and advancement of its therapeutic pipeline. This strategic investment is expected to accelerate the development of TGM-010 and further validate the Antibody Gene Signature technology. The company is poised to deepen its research into neurodegenerative diseases, aiming to translate its innovative approach into tangible clinical benefits for patients. Future growth will likely involve expanding clinical trials and potentially forging strategic partnerships to broaden market reach.
See full GenrAb company page
